{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:09:43Z","timestamp":1785841783730,"version":"3.56.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002946","name":"Deutsches Zentrum f\u00fcr Luft- und Raumfahrt","doi-asserted-by":"publisher","award":["01VSF16009"],"award-info":[{"award-number":["01VSF16009"]}],"id":[{"id":"10.13039\/501100002946","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00702-020-02291-y","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T05:08:17Z","timestamp":1610082497000},"page":"243-252","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Pharmacodynamic Drug\u2013Drug interactions of QT-prolonging drugs in hospitalized psychiatric patients"],"prefix":"10.1007","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5892-8993","authenticated-orcid":false,"given":"Gudrun","family":"Hefner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sermin","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle C.","family":"Roll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansgar","family":"Klimke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"2291_CR1","doi-asserted-by":"publisher","first-page":"e0148212","DOI":"10.1371\/journal.pone.0148212","volume":"11","author":"C Barbui","year":"2016","unstructured":"Barbui C et al (2016) Antipsychotic dose mediates the association between polypharmacy and corrected QT interval. PLoS ONE 11:e0148212. https:\/\/doi.org\/10.1371\/journal.pone.0148212","journal-title":"PLoS ONE"},{"key":"2291_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.psym.2017.10.009","volume":"59","author":"SR Beach","year":"2018","unstructured":"Beach SR, Celano CM, Sugrue AM, Adams C, Ackerman MJ, Noseworthy PA, Huffman JC (2018) QT prolongation, torsades de pointes, and psychotropic medications: a 5-year update. Psychosomatics 59:105\u2013122. https:\/\/doi.org\/10.1016\/j.psym.2017.10.009","journal-title":"Psychosomatics"},{"key":"2291_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12888-019-2056-0","volume":"19","author":"J Carmona-Huerta","year":"2019","unstructured":"Carmona-Huerta J et al (2019) Polypharmacy in a hospitalized psychiatric population: risk estimation and damage quantification. BMC Psychiatry 19:78. https:\/\/doi.org\/10.1186\/s12888-019-2056-0","journal-title":"BMC Psychiatry"},{"key":"2291_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1159\/000447034","volume":"85","author":"AF Carvalho","year":"2016","unstructured":"Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA (2016) The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom 85:270\u2013288. https:\/\/doi.org\/10.1159\/000447034","journal-title":"Psychother Psychosom"},{"key":"2291_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2019.03.008","author":"B Das","year":"2019","unstructured":"Das B, Rawat VS, Ramasubbu SK, Kumar B (2019) Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients. Therapie. https:\/\/doi.org\/10.1016\/j.therap.2019.03.008","journal-title":"Therapie"},{"key":"2291_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.4103\/0019-5545.166619","volume":"57","author":"N Desai","year":"2015","unstructured":"Desai N, Venkatesh CR, Kumar SS (2015) QT prolongation and torsades de pointes with psychotropic agents. Indian J Psychiatry 57:305\u2013308. https:\/\/doi.org\/10.4103\/0019-5545.166619","journal-title":"Indian J Psychiatry"},{"key":"2291_CR7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1017\/s1092852917000402","volume":"23","author":"A Elliott","year":"2018","unstructured":"Elliott A et al (2018) QTc interval in patients with schizophrenia receiving antipsychotic treatment as monotherapy or polypharmacy. CNS Spectr 23:278\u2013283. https:\/\/doi.org\/10.1017\/s1092852917000402","journal-title":"CNS Spectr"},{"key":"2291_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1041-2972.2005.0020.x","volume":"17","author":"MM Fulton","year":"2005","unstructured":"Fulton MM, Allen ER (2005) Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract 17:123\u2013132","journal-title":"J Am Acad Nurse Pract"},{"key":"2291_CR9","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jad.2011.10.033","volume":"136","author":"W Greil","year":"2012","unstructured":"Greil W, Haberle A, Haueis P, Grohmann R, Russmann S (2012) Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J Affect Disord 136:534\u2013542. https:\/\/doi.org\/10.1016\/j.jad.2011.10.033","journal-title":"J Affect Disord"},{"key":"2291_CR10","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s40263-014-0196-9","volume":"28","author":"M Hasnain","year":"2014","unstructured":"Hasnain M, Vieweg WV (2014) QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs 28:887\u2013920. https:\/\/doi.org\/10.1007\/s40263-014-0196-9","journal-title":"CNS Drugs"},{"key":"2291_CR11","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3109\/09540261.2013.836475","volume":"25","author":"G Hefner","year":"2013","unstructured":"Hefner G, Laib AK, Sigurdsson H, Hohner M, Hiemke C (2013) The value of drug and metabolite concentration in blood as a biomarker of psychopharmacological therapy. Int Rev Psychiatry 25:494\u2013508. https:\/\/doi.org\/10.3109\/09540261.2013.836475","journal-title":"Int Rev Psychiatry"},{"key":"2291_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1055\/s-0044-102009","volume":"52","author":"G Hefner","year":"2019","unstructured":"Hefner G, Hahn M, Hohner M, Roll SC, Klimke A, Hiemke C (2019) QTc time correlates with amitriptyline and venlafaxine serum levels in elderly psychiatric inpatients. Pharmacopsychiatry 52:38\u201343. https:\/\/doi.org\/10.1055\/s-0044-102009","journal-title":"Pharmacopsychiatry"},{"key":"2291_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C et al (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51:9\u201362. https:\/\/doi.org\/10.1055\/s-0043-116492","journal-title":"Pharmacopsychiatry"},{"key":"2291_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3238\/arztebl.2010.0543","volume":"107","author":"S Holt","year":"2010","unstructured":"Holt S, Schmiedl S, Thurmann PA (2010) Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int 107:543\u2013551. https:\/\/doi.org\/10.3238\/arztebl.2010.0543","journal-title":"Dtsch Arztebl Int"},{"key":"2291_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00213-017-4767-6","volume":"235","author":"G Kadra","year":"2018","unstructured":"Kadra G et al (2018) Antipsychotic polypharmacy prescribing and risk of hospital readmission. Psychopharmacology 235:281\u2013289. https:\/\/doi.org\/10.1007\/s00213-017-4767-6","journal-title":"Psychopharmacology"},{"key":"2291_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2003","unstructured":"Mangoni AA, Jackson SHD (2003) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6\u201314. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.02007.x","journal-title":"Br J Clin Pharmacol"},{"key":"2291_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1177\/2045125317721662","volume":"7","author":"AD Meid","year":"2017","unstructured":"Meid AD et al (2017) Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol 7:251\u2013264. https:\/\/doi.org\/10.1177\/2045125317721662","journal-title":"Ther Adv Psychopharmacol"},{"key":"2291_CR18","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1017\/s2045796015000906","volume":"25","author":"M Nos\u00e8","year":"2016","unstructured":"Nos\u00e8 M et al (2016) Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study. Epidemiol Psychiatr Sci 25:532\u2013540. https:\/\/doi.org\/10.1017\/s2045796015000906","journal-title":"Epidemiol Psychiatr Sci"},{"key":"2291_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa0806994","volume":"360","author":"WA Ray","year":"2009","unstructured":"Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360:225\u2013235. https:\/\/doi.org\/10.1056\/NEJMoa0806994","journal-title":"N Engl J Med"},{"key":"2291_CR20","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden DM (2004) Drug therapy: drug-induced prolongation of the QT interval. N Engl J Med 350:1013\u20131022","journal-title":"N Engl J Med"},{"key":"2291_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-014-1317-9","author":"HP Sigurdsson","year":"2014","unstructured":"Sigurdsson HP, Hefner G, Ben-Omar N, Kostlbacher A, Wenzel-Seifert K, Hiemke C, Haen E (2014) Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI. J Neural Transm. https:\/\/doi.org\/10.1007\/s00702-014-1317-9","journal-title":"J Neural Transm"},{"key":"2291_CR22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40264-018-0649-z","volume":"41","author":"M Simoons","year":"2018","unstructured":"Simoons M et al (2018) Limited evidence for risk factors for proarrhythmia and sudden cardiac death in patients using antidepressants: Dutch consensus on ECG monitoring. Drug Saf 41:655\u2013664. https:\/\/doi.org\/10.1007\/s40264-018-0649-z","journal-title":"Drug Saf"},{"key":"2291_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyu080","author":"CJ Spindelegger","year":"2014","unstructured":"Spindelegger CJ et al (2014) Cardiovascular adverse reactions during antidepressant treatment: a drug surveillance report of German-speaking countries between 1993 and 2010. Int J Neuropsychopharmacol. https:\/\/doi.org\/10.1093\/ijnp\/pyu080","journal-title":"Int J Neuropsychopharmacol"},{"key":"2291_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/070674371506000503","volume":"60","author":"H Takeuchi","year":"2015","unstructured":"Takeuchi H, Suzuki T, Remington G, Uchida H (2015) Antipsychotic polypharmacy and corrected QT interval: a systematic review. Can J Psychiatry 60:215\u2013222. https:\/\/doi.org\/10.1177\/070674371506000503","journal-title":"Can J Psychiatry"},{"key":"2291_CR25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/circoutcomes.113.000152","volume":"6","author":"JE Tisdale","year":"2013","unstructured":"Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, Kovacs RJ (2013) Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 6:479\u2013487. https:\/\/doi.org\/10.1161\/circoutcomes.113.000152","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2291_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1055\/s-0031-1286346","volume":"45","author":"S Unterecker","year":"2012","unstructured":"Unterecker S, Warrings B, Deckert J, Pfuhlmann B (2012) Correlation of QTc interval prolongation and serum level of citalopram after intoxication\u2014a case report. Pharmacopsychiatry 45:30\u201334. https:\/\/doi.org\/10.1055\/s-0031-1286346","journal-title":"Pharmacopsychiatry"},{"key":"2291_CR27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ijcard.2017.05.072","volume":"243","author":"E Vandael","year":"2017","unstructured":"Vandael E, Vandenberk B, Vandenberghe J, Pince H, Willems R, Foulon V (2017a) Incidence of torsade de pointes in a tertiary hospital population. Int J Cardiol 243:511\u2013515. https:\/\/doi.org\/10.1016\/j.ijcard.2017.05.072","journal-title":"Int J Cardiol"},{"key":"2291_CR28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11096-017-0446-2","volume":"39","author":"E Vandael","year":"2017","unstructured":"Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V (2017b) Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm 39:424\u2013432. https:\/\/doi.org\/10.1007\/s11096-017-0446-2","journal-title":"Int J Clin Pharm"},{"key":"2291_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/17843286.2017.1300217","volume":"72","author":"E Vandael","year":"2017","unstructured":"Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V (2017c) Cases of drug-induced torsade de pointes: a review of belgian cases in the eudravigilance database. Acta Clin Belg 72:385\u2013390. https:\/\/doi.org\/10.1080\/17843286.2017.1300217","journal-title":"Acta Clin Belg"},{"key":"2291_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11096-016-0414-2","volume":"39","author":"E Vandael","year":"2017","unstructured":"Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V (2017d) Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm 39:16\u201325. https:\/\/doi.org\/10.1007\/s11096-016-0414-2","journal-title":"Int J Clin Pharm"},{"key":"2291_CR31","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/jcp.0000000000000758","volume":"37","author":"E Vandael","year":"2017","unstructured":"Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V (2017e) Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol 37:540\u2013545. https:\/\/doi.org\/10.1097\/jcp.0000000000000758","journal-title":"J Clin Psychopharmacol"},{"key":"2291_CR32","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3238\/arztebl.2011.0687","volume":"108","author":"K Wenzel-Seifert","year":"2011","unstructured":"Wenzel-Seifert K, Wittmann M, Haen E (2011) QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int 108:687\u2013693. https:\/\/doi.org\/10.3238\/arztebl.2011.0687","journal-title":"Dtsch Arztebl Int"},{"key":"2291_CR33","unstructured":"Woosley RL, Heise CW, Gallo T, Tate J, Woosley D and Romero KA. www.CredibleMeds.org, QTdrugs List, [06\/2019], AZCERT, Inc 1822 Innovation Park Dr, Oro Valley, AZ 85755"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-020-02291-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-020-02291-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-020-02291-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T17:09:41Z","timestamp":1614445781000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-020-02291-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["2291"],"URL":"https:\/\/doi.org\/10.1007\/s00702-020-02291-y","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"assertion":[{"value":"4 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Gudrun Hefner, Martina Hahn, Sibylle C. Roll, Jan Wolff and Ansgar Klimke declare no conflicts of interest\/competing interests. Sermin Toto has been a member of an advisory board for Otsouka, and has received speaker\u2019s honoraria from Janssen Cilag, Lundbeck, Otsouka and Servier. Christoph Hiemke has received speaker\u2019s and consultancy fees from Stada, Lohmann Transdermal Systems and Otsuka during the last two years.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval in November 2017 in Hesse, Germany; reference number FF 116\/2017.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors consent to participate in this study and for publication of this study results.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and for publications"}}]}}